APR 8·Stock Titan▲
FDA clears Mesoblast Duchenne trial for disease affecting 15,000 U.S. children
Mesoblast has received FDA Investigational New Drug (IND) clearance to directly proceed with a registrational trial for Ryoncil in Duchenne muscular dystrophy (DMD). The trial will enroll 76 patients aged 5-9, with time-to-stand at nine months as the primary endpoint. This builds on Ryoncil's existing pediatric safety profile, preclinical efficacy in DMD models, and an FDA-approved manufacturing process.
APR 7·The Motley Fool Australia▼
Why Challenger, Lotus Resources, Mesoblast, and Wildcat shares are falling today
Shares of Challenger, Lotus Resources, Mesoblast, and Wildcat Resources are all falling today despite a general market gain. Challenger's shares are down despite a new partnership with Bank of Queensland, while Lotus Resources is down due to a production delay at its uranium mine caused by fire damage. Mesoblast's shares are falling after a sales update for its Ryoncil treatment may have disappointed investors, and Wildcat Resources saw a decline despite a drilling update showing an extension of mineralisation at one of its projects.
